Oncocyte Corporation (OCX) News

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

VitaGraft Kidney Expands Utility in Recurrent Primary Disease Patients

- Blood-based test differentiates between ABMR and IgAN, enabling faster and more effective treatment- Improved...

Form 8-K - Current report

Oncocyte Announces 1-For-20 Reverse Stock Split

IRVINE, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX) (the “Company”), a...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 8-K - Current report

Form DEF 14A - Other definitive proxy statements

Form 4 - Statement of changes in beneficial ownership of securities

Form PRE 14A - Other preliminary proxy statements

Form 8-K - Current report

Oncocyte Begins Manufacturing Transplant Blood Test

Over 1 million annual testing opportunities in US Q4 targeted for early access launch IRVINE, Calif., June...

Statement of Changes in Beneficial Ownership (4)

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...

Current Report Filing (8-k)

0001642380 false 0001642380 2023-06-06 2023-06-06 iso4217:USD xbrli:shares...

Proxy Statement (definitive) (def 14a)

      UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   SCHEDULE 14A (R...